Fig. 8

Effects of DOI and MA administration either alone or in combination on c-fos expression in different regions at 5 coronal levels in the PFC. Relative to the corresponding vehicle + vehicle treatment control group, DOI by itself (i.e. vehicle + DOI (1 mg/kg, i.p.)) significantly increased c-fos expression in the: (i) FrA, LO, and DLO at the level of − 2.68 mm relative to bregma (a, b); (ii) M1, M2, LO, and AI at the level of − 2.34 mm relative to bregma (c, d); (iii) M1, LO, and AI at the level of − 2.1 mm relative to bregma (e, f); (iv) S1, M1, PrL, IL, and AI at the level of − 1.98 mm relative to bregma (g, h) and (v) S1 and M1 at the level of − 1.7 mm relative to bregma (i, j). MA by itself (i.e. MA + vehicle group) significantly increased the expressions of c-fos in the: (i) PrL, VO, LO, and DLO at the level of − 2.68 mm relative to bregma (a, b); (ii) M2, Cg1, VO, and AI at the level of − 2.34 mm relative to bregma (c, d); (iii) M2, and AI at the level of − 2.1 mm relative to bregma (e, f). (iv) M2, Cg1, PrL, and AI at the level of − 1.98 mm relative to bregma (g, h). Combined treatment with MA + DOI significantly increased the expressions of c-fos in the: (i) FrA, PrL, LO, and DLO at the level of − 2.68 mm relative to bregma (a, b); (ii) M1, M2, and AI at the level of − 2.34 mm relative to bregma (c, d); (iii) M1, and AI at the level of − 2.1 mm relative to bregma (e, f); (iv) S1, Cg1, PrL and AI at the level of − 1.98 mm relative to bregma (g, h); and (v) S1 at the level of − 1.7 mm relative to bregma (i, j). There are no significant differences among comparisons of vehicle + DOI vs. MA + vehicle; vehicle + DOI vs. MA + DOI; and MA + vehicle vs. MA + DOI in the c-fos expressions in these brain regions. *p < 0.05, **p < 0.01, ***p < 0.001 vs. Vehicle + Vehicle treatment control group; one-way ANOVA followed by Tukey's test. Data are presented as means ± SEM